Hepion Pharmaceuticals Stock Price and Value Analysis

Should you buy Hepion Pharmaceuticals stock? (NasdaqCM:CTRV). Let's see how it does in our automated value investing analysis system.

CTRV Free Cash Flow Trend

Free Cash Flow trendline for CTRV
Free Cash Flow trendline for Hepion Pharmaceuticals

Hmm, we can't give any reliable projection for Hepion Pharmaceuticals's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company is not making money.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the CTRV Numbers

CTRV Price
(Hepion Pharmaceuticals stock price per share)
PE Ratio versus Sector 100% lower than other Unknown stocks
PE Ratio versus Industry 100% lower than other Unknown stocks
Free Cash Flow Jitter 44%

Is Hepion Pharmaceuticals Stock on Sale?

Based on our analysis, we believe that you should not buy Hepion Pharmaceuticals right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy CTRV Stock?

Does Hepion Pharmaceuticals have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.